OptiBiotix Health PLC Further sales expansion in Asia
06 July 2021 - 4:00PM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
06 July 2021
Opti B i otix Health plc
(" Opti Bi o t ix" or the "Company")
Further sales expansion in Asia
New Exclusive Distribution deal for CholBiome(R) in South
Korea
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, a nn o unces that its wholly-owned
subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered a
exclusive disbution deal with INSCOBEE INC ("Inscobee") for
CholBiome(R) in the Republic of Korea.
Inscobee was established in 1970 and is listed on Korea's major
stock market KOSPI since 1985. Its business activities consist of
four fast growing business fields: the Smart grid, Mobile Virtual
Network Operation, Cosmetics, and Bio-Tech, which includes its
pharmaceutical, neutraceuticals, and supplement products with
distribution in domestic and overseas markets. Inscobee's group
turover was 57.8 billion Korean Won (USD 52.2m) last year and they
are curently focused on expanding the health supplement area of
their business.
Inscobee sell and promote nutraceuticals through hospitals and a
consumer distribution base through Korean off-line channels such as
Holland & Barrett stores, hypermarkets, home-shopping, and
e-commerce channels including on-line malls, open markets,
influencer markets and live commerce markets.
This agreement with Inscobee is another milestone in a series of
deals which ProBiotix have entered into within Asia which help
build LP LDL(R) and CholBiome's reputation and brand awareness in
the region and open up the potentail for cross boarder e-commerce
trading in China. ProBiotix Health has substantial momentum in the
region, according to a recent article published in Nutraingredient
Asia: Probiotics and CVD: OptiBiotix extends CholBiome range to
APAC as blood pressure and cholesterol concerns rise
(nutraingredients-asia.com) .
Mr. Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health
commened: "Incobee is the ideal partner in the fast moving, highly
dynamic and competitive South Korean health food markets where
consumers seek innovative and effective natural solutions which
stand out in the market. We welcome Inscobee into a global team of
CholBiome(R) distributors serving medical doctors and
cardiovascular specialists and directly to consumers via
homeshopping, pharmacies and medical clinics. By entering deals on
CholBiome(R) and LP LDL(R) in India, China, Malaysia, Singapore,
Indonesia, Phillipines, Taiwan, Australia, and New Zealand,
ProBiotix is growing sales and developing a brand presence in these
strategically important Asian growth markets."
Mr. Seung-Hyeon Nam, Director of Inscobee Plc, commented: "At
Inscobee, we are very pleased to introduce CholBiome(R) products to
the Korean healthcare market. We believe CholBiome(R) has great
potential to fill the void of safe and beneficial cardiovascular
health needs in the nation and expect that it will play a big role
as a flaghship product of Inscobee's healthcare business. We look
forward to a long and successful partnership with ProBiotix
Health."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which
modify the human microbiome - the collective genome of the
microbes in the body - in order to prevent and manage human
disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading
academics in the development of microbial strains, compounds,
and formulations which are used as active ingredients and
supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix
to incorporate their human microbiome modulators into a
wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas
of focus include obesity, cardiovascular health, and diabetes.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUMWMUPGGQA
(END) Dow Jones Newswires
July 06, 2021 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
